Technology
Alterity Therapeutics to commercialise technology that breaks antibiotic resistance – Small Caps
The University of Queensland’s commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology…
The University of Queenslands commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology in combating superbugs.
UniQuest has given Alterity exclusive worldwide rights to use its zinc ionophore technology in developing and commercialising therapies that re-sensitise bacteria to antibiotics.
Once Alterity has begun receiving commercial revenue from commercialising the technology, it will make milestone and royalty payments to UniQuest…
-
Noosa News9 hours agoHow Lily Steele-Park took her rapist to court and won
-
General23 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business14 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Noosa News23 hours agoDarling Downs Zoo gives update on woman who lost her arm in lion attack